Jacobson Pharma Corporation

Jacobson Pharma Corporation Equity

The The Equity of Jacobson Pharma Corporation (2633.HK) as of Nov 5, 2026 is 2.32 B HKD. In the previous year, The Equity was 2.45 B HKD — a change of -5.59% (lower).

Equity

2.32 BHKD

YoY

-5.59%

Last updated:

In 2026, Jacobson Pharma Corporation's equity was 2.32 B HKD, a -5.59% increase from the 2.45 B HKD equity in the previous year.

The Jacobson Pharma Corporation Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
2.65 B HKD
Jan 1, 2020
2.54 B HKD
Jan 1, 2021
2.39 B HKD
Jan 1, 2022
2.49 B HKD
Jan 1, 2023
2.74 B HKD
Jan 1, 2024
2.37 B HKD
Jan 1, 2025
2.45 B HKD
Jan 1, 2026
2.32 B HKD
The Jacobson Pharma Corporation Equity history
YEAREquityYoY
2.32 BHKD-5.59%
2.45 BHKD+3.42%
2.37 BHKD-13.32%
2.74 BHKD+9.85%
2.49 BHKD+4.25%
2.39 BHKD-5.83%
2.54 BHKD-4.13%
2.65 BHKD+33.98%
1.98 BHKD+12.94%
1.75 BHKD+92.90%
906.88 MHKD-5.27%
957.34 MHKD+9.05%
877.89 MHKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jacobson Pharma Corporation Stock analysis

What does Jacobson Pharma Corporation do? Jacobson Pharma Corp. Ltd. generates revenue through its Generic Drugs segment, which develops, manufactures, and distributes off-patent medicines for public and private sectors. The Branded Healthcare segment offers branded medicines, proprietary Chinese medicines, and health and wellness products. Both segments operate primarily in Hong Kong, serving healthcare providers and consumers seeking cost-effective pharmaceutical solutions. The company employs 1,789 full-time employees to support its operations across these segments. The Generic Drugs segment focuses on off-patent medicines for various therapeutic uses, targeting hospitals, clinics, and pharmacies in both public and private healthcare systems. The Branded Healthcare segment caters to consumers and healthcare providers through branded pharmaceuticals and wellness products, emphasizing proprietary Chinese medicines as a key offering. Revenue streams are derived from direct sales of these products within Hong Kong's healthcare market. Jacobson Pharma's business model relies on the dual revenue streams from generic and branded pharmaceuticals. The company's product portfolio includes off-patent medicines under the Generic Drugs segment and branded medicines under the Branded Healthcare segment, both contributing to its overall sales. The firm's operations are structured around these two segments, with all activities concentrated in Hong Kong. Jacobson Pharma Corporation is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Jacobson Pharma Corporation's Equity

Jacobson Pharma Corporation's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Jacobson Pharma Corporation's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Jacobson Pharma Corporation's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Jacobson Pharma Corporation's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Jacobson Pharma Corporation’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Jacobson Pharma Corporation stock

The Equity of Jacobson Pharma Corporation is 2.32 B HKD in 2026.

The Equity of Jacobson Pharma Corporation changed from 2.45 B HKD to 2.32 B HKD, representing a -5.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Jacobson Pharma Corporation since 2006 – with annual values, charts, and detailed analysis.

The Equity's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Jacobson Pharma Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jacobson Pharma Corporation

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jacobson Pharma Corporation